Journal Article10.1128/CMR.12.1.40
Current and Emerging Azole Antifungal Agents
1.1K
TL;DR: Present and future uses of the currently available azole antifungal agents in the treatment of systemic and superficial fungal infections are described and a brief overview of the current status of in vitro susceptibility testing and the growing problem of clinical resistance to the azoles is provided.
read more
Abstract: Major developments in research into the azole class of antifungal agents during the 1990s have provided expanded options for the treatment of many opportunistic and endemic fungal infections. Fluconazole and itraconazole have proved to be safer than both amphotericin B and ketoconazole. Despite these advances, serious fungal infections remain difficult to treat, and resistance to the available drugs is emerging. This review describes present and future uses of the currently available azole antifungal agents in the treatment of systemic and superficial fungal infections and provides a brief overview of the current status of in vitro susceptibility testing and the growing problem of clinical resistance to the azoles. Use of the currently available azoles in combination with other antifungal agents with different mechanisms of action is likely to provide enhanced efficacy. Detailed information on some of the second-generation triazoles being developed to provide extended coverage of opportunistic, endemic, and emerging fungal pathogens, as well as those in which resistance to older agents is becoming problematic, is provided.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Liposomal amphotericin B: clinical experience and perspectives.
TL;DR: This review will focus primarily on recent liposomal amphotericin B experience and attempt to put its use into perspective considering other available antifungal agents.
List of papers
Optimis parentibus,Ingemar Eriksson,Farvah Mahmoudi,Oscar Stål +3 more
- 20 Jun 2022
TL;DR: Stål et al. as discussed by the authors derived the charged Higgs boson mass and couplings for constrained scenarios in the minimal supersymmetric standard model (MSSM) with grand unification, and for general two-Higgs-doublet models.
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever
Thomas J. Walsh,Peter G. Pappas,Drew J. Winston,Hillard M. Lazarus,Finn Bo Petersen,John Raffalli,Saul Yanovich,Patrick J. Stiff,Richard N. Greenberg,Gerald R. Donowitz,Mindy G. Schuster,Annette C. Reboli,John R. Wingard,Carola A.S. Arndt,John F. Reinhardt,Susan Hadley,Robert W. Finberg,Michel Laverdière,John R. Perfect,Gary Garber,Giuseppe Fioritoni,Eli Anaissie,Jeanette Y. Lee +22 more
TL;DR: Voriconazole is a suitable alternative to amphotericin B preparations for empirical antifungal therapy in patients with neutropenia and persistent fever in a randomized, international, multicenter trial.
Gene expression profiling in liver and testis of rats to characterize the toxicity of triazole fungicides
Douglas B. Tully,Wenjun Bao,Amber K. Goetz,Chad R. Blystone,Hongzu Ren,Judith E. Schmid,Lillian F. Strader,Carmen R. Wood,Deborah S. Best,Michael G. Narotsky,Douglas C. Wolf,John C Rockett,David J. Dix +12 more
TL;DR: Gene expression profiles helped identify possible toxicological mechanisms of the triazole fungicides and demonstrated the similarities of toxicogenomic responses in liver between all four triazoles and in testis between myclobutanil and triadimefon.
Genomic Profiling in Nuclear Receptor-Mediated Toxicity
TL;DR: The future of drug discovery, design and optimization, and risk assessment of chemical toxicants that activate NRs will inevitably involve genomic profiling, and this review will focus on genomics studies related to PPAR, CAR, PXR, RXR, LXR, FXR, and AHR.
References
•Book
Principles and Practice of Infectious Diseases
Gerald L. Mandell,R. Gordon Douglas,John E. Bennett +2 more
- 01 Mar 1989
TL;DR: This updated and expanded edition now offers 297 chapters that cover the basic principles of diagnosis and management, major clinical syndromes, all important pathogenic microbes and the diseases they cause, plus a number of specialised topics useful to the practitioner.
14.4K
National Committee for Clinical Laboratory Standards.
TL;DR: Many members of the Academy of Pediatrics seem to be generally unaware of the fact that the Academy has participated for ten years in a very interesting and valuable organization, the National Committee for Clinical Laboratory Standards (NCCLS).
14.1K
Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.
TL;DR: This review summarizes the factors that contribute to antifungal drug resistance on three levels: clinical factors that result in the inability to successfully treat refractory disease; cellular factors associated with a resistant fungal strain; and molecular factors that are ultimately responsible for the resistance phenotype in the cell.
1.4K
The Merck Index
TL;DR: The Merck Index of Chemicals and Drugs is an encyclopedia for the Chemist, Pharmacist, Physician and Allied Professions and thumb-indexed, 8 dollars.
1.3K